专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明专利

JP2013047243A 6-o-substituted ketolide having antibacterial activity 审中-公开
标题翻译：具有抗生素活性的6-O-取代的硬脂酸乙酯
公开(公告)号：JP2013047243A
公开(公告)日：2013-03-07
申请号：JP2012228250
申请日：2012-10-15
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： OR YAT SUN , MA ZHENKUN , CLARK RICHARD F , CHU DANIEL T , PLATTNER JACOB J
IPC分类号： C07H17/08 , A61K31/7048 , A61K31/7056 , A61P31/04
CPC分类号： C07H17/08 , Y02P20/55
摘要： PROBLEM TO BE SOLVED: To provide new semi-synthesized macrolides having antibacterial activity, a pharmaceutical composition including these compounds, and a medical treatment method of remedy.SOLUTION: There is provided a 6-O-substituted erythromycin ketolide derivative expressed by formula (IV-A), where in formula, Rc is hydrogen or a hydroxy-protective group; R is a substituted methyl group; A, B, D and E are each selected from hydrogen, a 1-6C alkyl which may be substituted by a substituent, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, hydroxy, 1-6C alkoxy, and halogen of Br, Cl, F or I, or the like, under conditions that at least two of A, B, D and E are both hydrogen.
摘要翻译：要解决的问题：提供具有抗菌活性的新的半合成大环内酯类，包括这些化合物的药物组合物和补救药物治疗方法。解决方案：提供由式（IV-A）表示的6-O-取代的红霉素酮内酯衍生物，其中在式中，Rc是氢或羟基保护基; R是取代的甲基; A，B，D和E各自选自氢，可被取代基取代的1-6C烷基，芳基，取代的芳基，杂芳基，取代的杂芳基，杂环烷基，羟基，1-6C烷氧基和Br的卤素， Cl，F或I等，在A，B，D和E中的至少两个都是氢的条件下。版权所有（C）2013，JPO＆INPIT

12. 发明专利

JP2013040192A POLYMORPHIC AND OTHER CRYSTALLINE FORM OF cis-FTC 审中-公开
标题翻译：顺式FTC的多晶和其他晶体形式
公开(公告)号：JP2013040192A
公开(公告)日：2013-02-28
申请号：JP2012229555
申请日：2012-10-17
申请人： Gilead Sciences Inc , ギリード・サイエンシズ・インコーポレーテッド , Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： PHARES KENNETH R , LAW DEVALINA , HU YUERONG
IPC分类号： C07D411/04 , A61K31/513 , A61P1/16 , A61P31/12 , A61P31/18 , A61P31/20
CPC分类号： C07D411/04
摘要： PROBLEM TO BE SOLVED: To provide new polymorphic and other crystalline forms of FTC, to provide a new method for preparing and isolating polymorphic and other crystalline forms of FTC and to provide a use of FTC polymorphic body, FTC of other phases and treatment purpose.SOLUTION: A solid phase of (-)-cis-FTC, which can be distinguished from form (I) (-)-cis-FTC by means of X-ray power diffraction pattern, thermal properties and methods of manufacture and is designated herein as amorphous (-)-FTC and (form II (-)-cis-FTC) and (form III (-)-cis FTC), is provided. Likewise, hydrated crystalline form of (±)-cis-FTC (that is, cis-FTC of racemic body) which can be distinguished from other forms of FTC by means of X-ray power diffraction pattern, thermal properties and methods of manufacture, and a dehydrated form of the hydrate are provided. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. These forms are particularly desirably used for treating HIV or hepatitis B.
摘要翻译：要解决的问题：提供新的多晶型和其他结晶形式的FTC，以提供制备和分离FTC的多晶型和其他结晶形式的新方法，并提供使用FTC多态体，其他阶段的FTC，治疗目的。解决方案：（ - ） - 顺式 - FTC的固相，其可以通过X射线功率衍射图，热性质和制造方法与形式（I）（ - ） - 顺式 - FTC区分开来在本文中被指定为无定形（ - ） - FTC和（形式II（ - ） - 顺式 - FTC）和（形式III（ - ） - 顺式FTC）。同样地，通过X射线功率衍射图，热性质和制造方法可以与其他形式的FTC区分（±） - 顺式 - FTC（即外消旋体的顺式-FTC）的水合晶形，并提供水合物的脱水形式。这些FTC形式可用于制造其他形式的FTC或药物组合物。这些形式特别适合用于治疗艾滋病毒或乙型肝炎。版权所有：（C）2013，JPO＆INPIT

13. 发明专利

JP2012149078A Process for preparing formulation of lipid-regulating drug 审中-公开
标题翻译：制备脂质调节药物的方法
公开(公告)号：JP2012149078A
公开(公告)日：2012-08-09
申请号：JP2012063143
申请日：2012-03-21
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： QIU YIHING , WARDROP JACQUELINE
IPC分类号： A61K31/216 , A61K9/16 , A61K9/20 , A61K9/48 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/36 , A61P3/06
CPC分类号： A61K31/216 , A61K9/1623 , A61K9/1635 , A61K9/1652
摘要： PROBLEM TO BE SOLVED: To provide small particles of lipid-regulating drugs, more preferably fenofibrate, having comparable dissolution and absorption characteristics to the particles of such drugs prepared by the prior art techniques without the need of micronizing the lipid-regulating drug or utilizing surfactants.SOLUTION: A process for preparing a formulation of a lipid-regulating drug comprises dissolving the lipid-regulating drug such as fenofibrate in a solvent free of surfactant, premixing an excipient such as lactose, starch, polyvinyl pyrrolidone, and magnesium stearate, wet granulating the drug solution/excipient mixture, drying the mixture and forming a final dosage form.
摘要翻译：要解决的问题：提供小颗粒的脂质调节药物，更优选非诺贝特，其具有与通过现有技术制备的这些药物的颗粒相当的溶解和吸收特性，而不需要使脂质调节药物微粉化或利用表面活性剂。解决方案：制备脂质调节药物的制剂的方法包括将脂质调节药物如非诺贝特溶于不含表面活性剂的溶剂中，预先混合赋形剂如乳糖，淀粉，聚乙烯吡咯烷酮和硬脂酸镁，湿法造粒药物溶液/赋形剂混合物，干燥混合物并形成最终剂型。版权所有（C）2012，JPO＆INPIT

14. 发明专利

JP2012105649A Antigen construct useful in detection and identification of antibody to hiv 有权
标题翻译：抗原结构可用于检测和鉴定抗艾滋病毒
公开(公告)号：JP2012105649A
公开(公告)日：2012-06-07
申请号：JP2011272432
申请日：2011-12-13
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： HACKETT JOHN R JR , YAMAGUCHI JULIE , GOLDEN ALAN M , BRENNAN CATHERINE A , HICKMAN ROBERT K
IPC分类号： C12N15/09 , G01N33/53 , A61K39/00 , C07K14/155 , C07K14/16 , C07K19/00 , C12N1/21 , C12N15/49 , G01N33/569
CPC分类号： C07K14/005 , A61K39/00 , C07K2319/00 , C12N2740/16122 , G01N2333/162
摘要： PROBLEM TO BE SOLVED: To provide a new antigen construct useful as a reagent in immunoassay for detection and identification of antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O and human immunodeficiency virus type 2 (HIV-2), polynucleotides useful for the preparation of antigens, DNA clone, expression vectors, and transformed host cells.SOLUTION: There are provided isolated HIV-1 group O env polypeptides obtained from the HIV-1 isolate HAM112, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 group O env polypeptides and HIV-1 group M env polypeptide and (b) additional antigen constructs containing additional group O sequences.
摘要翻译：待解决的问题：提供一种新的抗原构建体，用作免疫测定中用于检测和鉴定1型人类免疫缺陷病毒（HIV-1）组M，HIV-1组O和人类免疫缺陷病毒类型的抗体的试剂 2（HIV-2），可用于制备抗原的多核苷酸，DNA克隆，表达载体和转化的宿主细胞。提供了从HIV-1分离株HAM112获得的分离的HIV-1组O env多肽的分离株，以及（a）包含HIV-1基因O型多肽中的一种或多种的融合物的抗原构建体， HIV-1组M env多肽和（b）另外的含有另外的O组的抗原构建体。版权所有（C）2012，JPO＆INPIT

15. 发明专利

JP2012072145A Condensed aza bicyclic compound inhibiting vanilloid receptor subtype 1 (vr1) receptor 审中-公开
标题翻译：浓缩AZA双相化合物抑制VANILLOID受体亚型1（VR1）受体
公开(公告)号：JP2012072145A
公开(公告)日：2012-04-12
申请号：JP2011226490
申请日：2011-10-14
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： BAYBURT EROL K , DIDOMENICO STANLEY JR , DRIZIN IRENE , GOMTSYAN ARTHUR R , KOENIG JOHN R , PERNER RICHARD J , SCHMIDT ROBERT G JR , TURNER SEAN C , WHITE TAMMIE K , ZHENG GUO ZHU , LEE CHIH-HUNG
IPC分类号： C07D209/08 , A61K31/404 , A61K31/416 , A61K31/454 , A61K31/46 , A61K31/472 , A61K31/4725 , A61K31/496 , A61K31/502 , A61K31/5377 , A61K31/541 , A61K31/55 , A61P13/00 , A61P25/04 , A61P29/00 , A61P43/00 , C07D217/02 , C07D217/24 , C07D231/56 , C07D237/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02
摘要： PROBLEM TO BE SOLVED: To provide a novel VR1 antagonist useful for treatment of pain, inflammatory thermalgesia, urorrhea and bladder hyperactivity.SOLUTION: The compound is represented by formula (I) (wherein Xto Xare each a nitrogen atom or the like; R, Rand Rare each a hydrogen atom or the like; Zand Zare each an oxygen atom or the like; and L is an alkenylene or the like).
摘要翻译：要解决的问题：提供一种新颖的VR1拮抗剂，可用于治疗疼痛，炎症性热痛，尿痛和膀胱多动症。解决方案：化合物由式（I）表示（其中X 1 至X 5 分别为氮原子每个都是R＆lt; SB POS =“POST”> 8a ，R 8b 和R 9 氢原子等; Z 1 ，Z 2 分别为氧原子等; L为亚烯基或类似物）。版权所有（C）2012，JPO＆INPIT

16. 发明专利

JP2012045429A Noninvasive measurement instrument 有权
标题翻译：非测量仪器
公开(公告)号：JP2012045429A
公开(公告)日：2012-03-08
申请号：JP2011267232
申请日：2011-12-06
申请人： Abbott Lab , Toshiba Medical Systems Corp , アボット・ラボラトリーズAbbott Laboratories , 東芝メディカルシステムズ株式会社
发明人： KANAYAMA SHOICHI , KHALIL OMAR S , YEH SHU-JEN
IPC分类号： A61B5/1455
摘要： PROBLEM TO BE SOLVED: To improve calibration accuracy to seasonal and psychological variation of tissue property.SOLUTION: A noninvasive measurement instrument has a measurement probe 1 supposed to get into touch with a trial subject, a light source 6 and a photodetector 7 to be connected to the measurement probe, and a computer section 5 for controlling the light source and photodetector to optically and noninvasively measure information relating to glucose in the trial subject and predict the value of glucose by a calibration model from an output of the photodetector. The computer section updates the calibration model by executing regression estimation based on the acquired data by noninvasive measurement on a different day and the corresponding reference measurement value and predicts glucose density from the acquired data by noninvasive measurement by using the updated calibration model.
摘要翻译：要解决的问题：提高校准精度对组织属性的季节和心理变化。解决方案：无创测量仪器具有测试探头1，该测量探针1应与试验对象接触，要连接到测量探针的光源6和光电检测器7以及用于控制光源的计算机部分5 光电检测器光学和非侵入性地测量与试验对象中的葡萄糖相关的信息，并且通过来自光电检测器的输出的校准模型预测葡萄糖的值。计算机部分通过基于所获取的数据通过不同日期的无创测量和相应的参考测量值执行回归估计来更新校准模型，并且通过使用更新的校准模型通过非侵入式测量从所获取的数据中预测葡萄糖浓度。版权所有（C）2012，JPO＆INPIT

17. 发明专利

JP2012021006A Hiv protease-inhibiting sulfonamides 审中-公开
标题翻译：艾滋病毒抗体抑制磺酰胺
公开(公告)号：JP2012021006A
公开(公告)日：2012-02-02
申请号：JP2011177726
申请日：2011-08-15
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： FLENTGE CHARLES A , CHEN HUI-JU , DEGOEY DAVID A , FLOSI WILLIAM J , GRAMPOVNIK DAVID J , HUANG PEGGY P , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , MADIGAN DAROLD L , RANDOLPH JOHN T , SUN MINGHUA , YEUNG MING C , ZHAO CHEN
IPC分类号： C07C311/18 , A61K31/165 , A61K31/17 , A61K31/175 , A61K31/18 , A61K31/195 , A61K31/221 , A61K31/277 , A61K31/325 , A61K31/341 , A61K31/35 , A61K31/381 , A61K31/4166 , A61K31/4168 , A61K31/4174 , A61K31/4178 , A61K31/4184 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/437 , A61K31/4402 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/65 , A61K45/06 , A61P31/18 , C07C311/17 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/75 , C07D213/78 , C07D233/32 , C07D233/34 , C07D233/40 , C07D233/72 , C07D277/28 , C07D277/46 , C07D277/48 , C07D307/14 , C07D307/20 , C07D307/42 , C07D333/20 , C07D333/68 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/10 , C07D409/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D493/04
CPC分类号： C07D471/04 , A61K31/175 , A61K31/18 , A61K31/195 , A61K31/277 , A61K31/4168 , A61K31/65 , A61K45/06 , C07D213/30 , C07D213/40 , C07D213/78 , C07D233/32 , C07D233/72 , C07D277/28 , C07D277/46 , C07D277/48 , C07D307/20 , C07D307/42 , C07D401/06 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/10 , C07D409/06 , C07D417/06 , C07D417/14 , C07D493/04 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide an improved HIV protease inhibitor that is very potent, that has reduced side-effects and that is effective against resistant strains of HIV.SOLUTION: This invention relates to: a compound of formula (I) as the HIV protease inhibitor; or a pharmaceutically acceptable salt form, stereoisomer, ester, salt of the ester, prodrug, salt of the prodrug, or combination thereof.
摘要翻译：要解决的问题：提供非常有效的改进的HIV蛋白酶抑制剂，其具有减少的副作用，并且对HIV的抗性菌株是有效的。解决方案：本发明涉及：作为HIV蛋白酶抑制剂的式（I）化合物; 或其药学上可接受的盐形式，立体异构体，酯，酯的盐，前药，前药的盐或其组合。版权所有（C）2012，JPO＆INPIT

18. 发明专利

JP2011236232A Solid pharmaceutical dosage form 有权
标题翻译：固体药物剂型
公开(公告)号：JP2011236232A
公开(公告)日：2011-11-24
申请号：JP2011149721
申请日：2011-07-06
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： ROSENBERG JOERG , REINHOLD ULRICH , LIEPOLD BERND , DERNDL GUNTHER , BREITENBACH JOERG , ALANI LAMAN , GHOSH SOUMOJEET
IPC分类号： A61K31/427 , A61K9/14 , A61K9/20 , A61K9/28 , A61K31/425 , A61K31/513 , A61K47/14 , A61K47/32 , A61P31/18 , A61P43/00
CPC分类号： A61K31/425 , A61K9/146 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2866
摘要： PROBLEM TO BE SOLVED: To provide a solid pharmaceutical dosage form that gives improved oral bioavailability for inhibitors of HIV protease.SOLUTION: The solid pharmaceutical dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant. The pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50°C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
摘要翻译：待解决的问题：提供一种固体药物剂型，其可以改善HIV蛋白酶抑制剂的口服生物利用度。解决方案：固体药物剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体。具有至少约50℃的Tg的药学上可接受的水溶性聚合物。优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。版权所有：（C）2012，JPO＆INPIT

19. 发明专利

JP2011139703A Elongase gene and use thereof 有权
标题翻译：延长基因及其使用
公开(公告)号：JP2011139703A
公开(公告)日：2011-07-21
申请号：JP2011014983
申请日：2011-01-27
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： MUKERJI PRADIP , LEONARD AMANDA EUN-YEONG , HUANG YUNG-SHENG , THURMOND JENNIFER , KIRCHNER STEPHEN J , PARKER-BARNES JENNIFER M , DAS TAPAS
IPC分类号： A01H5/00 , C12N15/09 , A01K67/027 , A23C11/02 , A23D9/00 , A23K1/14 , A23K1/16 , A23K1/175 , A23L1/30 , A61K8/30 , A61K8/36 , A61K8/60 , A61K8/64 , A61K31/201 , A61K31/202 , A61K38/00 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/24 , A61K47/26 , A61K47/36 , A61P1/04 , A61P3/02 , A61P3/06 , A61P3/10 , A61P3/14 , A61P7/02 , A61P9/00 , A61P9/08 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P19/02 , A61P19/10 , A61P21/00 , A61P25/28 , A61P29/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61Q19/00 , C12N1/14 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/00 , C12N9/10 , C12N15/54 , C12N15/82 , C12P7/40 , C12P7/64 , C12R1/645 , C12R1/865
CPC分类号： A61K8/361 , A01K2217/05 , A23D9/00 , A23K20/158 , A61K8/606 , A61K8/64 , A61K31/202 , A61K38/00 , A61K2800/86 , A61Q19/00 , C12N9/1029 , C12N15/8247 , C12P7/6409 , C12P7/6427 , C12P7/6463 , C12P7/6472
摘要： PROBLEM TO BE SOLVED: To identify four genes involved in an elongation of polyunsaturated acid (i.e., "elongase"); and to provide a use thereof. SOLUTION: Two of four genes involved in an elongation of polyunsaturated acid (i.e., "elongase") are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogama linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ω6-docosapentaenoic acid or ω3-docosapentaenoic acid, added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：待解决的问题：鉴定涉及多不饱和酸延伸的四个基因（即“延长酶”）; 并提供其使用。解决方案：涉及多不饱和酸延伸的四个基因中的两个（即“延长酶”）也参与单不饱和脂肪酸的延伸。特别地，延长酶用于将γ-亚麻酸（GLA）转化为二氨基亚麻酸（DGLA）和将DGLA或20：4n-3转化为二十碳五烯酸（EPA）。 DGLA可以用于生产多不饱和脂肪酸，例如花生四烯酸（AA），二十二碳六烯酸（DHA），EPA，肾上腺素，ω6-二十二碳烯酸或ω3-二十二碳五烯酸，添加到药物组合物，营养组合物，动物饲料，以及化妆品等其他产品。版权所有（C）2011，JPO＆INPIT

20. 发明专利

JP2011097946A Il-18 binding protein 审中-公开
标题翻译： IL-18结合蛋白
公开(公告)号：JP2011097946A
公开(公告)日：2011-05-19
申请号：JP2010280298
申请日：2010-12-16
申请人： Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
发明人： GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
IPC分类号： C12N15/09 , A61K31/436 , A61K31/4375 , A61K31/573 , A61K38/00 , A61K39/395 , A61K45/00 , A61K45/06 , A61K47/10 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/40 , A61K47/42 , A61P1/04 , A61P1/16 , A61P3/00 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/04 , A61P17/06 , A61P17/14 , A61P19/00 , A61P19/02 , A61P21/00 , A61P25/00 , A61P25/04 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P27/02 , A61P31/00 , A61P31/04 , A61P31/16 , A61P31/18 , A61P31/20 , A61P33/00 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/06 , A61P37/08 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/532 , G01N33/68
CPC分类号： G01N33/6869 , A61K2039/505 , C07K16/244 , C07K2317/33 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： PROBLEM TO BE SOLVED: To provide an antibody which binds to human interleukin-18 (hIL-18), to provide a method for producing the same; and to provide a method for using the same. SOLUTION: There are provided a neutrally binding protein which is an antibody comprising immune globulin heavy chain and light chain having specific amino acid sequences and specifically binding to human IL-18, and has an ability to neutralize IL-18; a method for producing the antibody; and a use for detecting hIL-18 or treating a human testee suffering from a disease wherein the activity of hIL-18 is harmful. COPYRIGHT: (C)2011,JPO&INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式